Hierarchical clustering demonstrated that glucose and FAO metabolic pathways did not differ between the classical, mesenchymal, and proneural/neural GBM subtypes, offering a potentially wide-ranging therapeutic avenue (Figure 1A), compared to therapies targeting specific genetic mutations (e.g., EGFR and IDH1). This evidence concerns the gene EGFR and glioblastoma.